Angina Pectoris Drugs Market

Angina Pectoris Drugs Market Size and Forecast

The global Angina Pectoris Drugs Market is valued at USD 11.68 Billion in 2024 and is projected to reach a value of USD 18.56 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 4.3% between 2025 and 2035.

Angina Pectoris Drugs Market Key Highlights

• Based on the Type, the Stable Angina category accounted for significant market share of 50.5% in Angina Pectoris Drugs market industry in 2024
• In 2024, by Drug Class, Beta Blockers dominated the market with significant Angina Pectoris Drugs market share of 37.5%
• By Distribution Channel, Hospital Pharmacy dominated the Angina Pectoris Drugs market with market share of 46.7% in 2024
• North America dominated the Angina Pectoris Drugs market industry with 39.4% market share in 2024
• Asia Pacific region is anticipated to grow at the highest CAGR during the forecast period in Angina Pectoris Drugs market industry

Based on the provided market data, Vantage Market Research offers customizations in the reports to meet the specific needs of clients.

Angina Pectoris Drugs Market Growth Factor

Growing Prevalence of Chronic Angina Pectoris

Chronic stable angina pectoris affects approximately 2.0–4.0% of the population in major markets such as the U.S., U.K., France, Italy, Germany, Spain, and Japan. According to the American Heart Association (AHA), about 9 million persons in the U.S. suffer chronic angina pectoris. The increased prevalence of this ailment, which is mostly caused by an aging population and rising cardiovascular disease risk factors such as obesity, diabetes, and hypertension, is greatly boosting the demand for efficient angina pectoris treatments. Improved awareness and diagnosis rates have led to a growing patient pool, propelling the Angina Pectoris Drugs industry.

Advancements in Clinical Research and Increasing Drug Approval

Regulatory approvals and advancement in clinical research is changing the landscape of Angina Pectoris Drugs market. Novel medications, such as gene therapy and biologics, are emerging as alternatives to traditional surgical and pharmaceutical treatments for angina pectoris. Gene therapy, in particular, is emerging as a revolutionary method, with multiple Phase II/III clinical trials under progress. For instance, Taxus Cardium's adenovector DNA-based gene therapy, which is currently in the last stages of clinical research. Furthermore, advancement in drug delivery systems including targeted therapy and extended-release formulations which improves the efficacy and safety of angina drugs.

Angina Pectoris Drugs Market Opportunity Factor

Rising Demand for Retail Pharmacies

The increasing accessibility of angina pectoris medications through retail pharmacies presents a major opportunity for market growth. The rise of retail pharmacy networks, particularly in industrialized countries, has increased medication availability, making it easier for patients to access prescriptions and over-the-counter medications for angina treatment. Retail pharmacies offer a more convenient alternative to hospital-based care, including speedier access to prescriptions, improved patient adherence, and pharmacist-led counseling. The expansion of the Angina Pectoris Drugs market is further supported by the growth of pharmacy chains, partnerships with healthcare providers, and the incorporation of digital prescriptions. Government measures to develop retail pharmacy infrastructure and increase the affordability of cardiovascular drugs in emerging markets.

Type Insights

​The Type segment is divided into Stable Angina, Unstable Angina, Microvascular Angina, Prinzmetal Angina. The Stable Angina segment held the dominant share in 2024, accounting for significant Angina Pectoris Drugs market share of 50.5%.

• Stable Angina held the most market share in 2024 in market and is expected to maintain its dominance throughout the forecast period. The prevalence of chronic stable angina continues to rise, with nearly half of affected individuals experiencing it as the first indication of ischemic heart disease. Exposure to cold temperatures or physical activity are common triggers for stable angina, which contributes to the segment's enlargement. The Angina Pectoris Drugs market's dominance is attributed to ongoing research and development, increased public awareness, and effective treatment options.
• The unstable angina segment is projected to witness the fastest growth, with a 5.9% CAGR over the forecast period. The increased incidence of cardiovascular diseases (CVDs) is largely due to the growing older population and lifestyle factors such as smoking, poor diets, and physical inactivity. The rise in CVD incidence has increased demand for angina pectoris drugs, particularly for unstable angina, a more serious condition. Improved healthcare infrastructure, advances in testing tools, and increased knowledge of CVDs have allowed for quicker detection of unstable angina. Early detection enables rapid treatment, driving Angina Pectoris Drugs market growth.

Drug Class Insights

The Drug Class segment is divided into Beta Blockers, Calcium Antagonists, Nitrates, Anticoagulants, Anti-Platelets, Other Drug Classes. In 2024, the Beta Blockers segment held largest share of 37.5% in the Angina Pectoris Drugs market.

• In 2024, the Beta Blockers segment held the largest share of the market revenue. Beta Blockers widespread use as a first-line treatment for angina pectoris is a key factor behind this dominance in Angina Pectoris Drugs market. Additionally, the growing elderly population and strategic efforts by market players to improve the commercial availability of beta blockers have further boosted their adoption. By slowing the heart rate and reducing the strength of heart muscle contractions, these medications play a vital role in managing angina, particularly among aging individuals
• Anticoagulants segment is projected to expand significantly over the forecast period. The rising prevalence of angina pectoris has increased the demand for anticoagulant drugs, which are commonly prescribed to prevent blood clot formation and reduce the risk of cardiovascular complications. The introduction of novel oral anticoagulants (NOACs) has transformed the market, offering safer and more effective alternatives to traditional warfarin, thereby accelerating Angina Pectoris Drugs market growth.

Distribution Channel Insights

The Distribution Channel segment is divided into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy. In 2024, the Hospital Pharmacy segment held largest share of 46.7% in the Angina Pectoris Drugs market.

• In 2024, the Hospital Pharmacy segment held largest share in the market. This dominance is largely due to the increasing number of patients seeking treatment in hospitals, which are equipped with advanced medical infrastructure and specialized facilities. Additionally, the expansion of healthcare institutions, coupled with the implementation of effective policies, has further contributed to the market growth of this segment
• Online pharmacy segment is expected to experience the fastest growth, with a projected CAGR of 6.1% during the forecast period. Online pharmacies have become a convenient option for obtaining angina pectoris medications, allowing patients to order prescriptions from home while accessing a wide variety of treatment options. Competitive pricing and home delivery services have made these platforms particularly beneficial for individuals with mobility challenges, further driving Angina Pectoris Drugs market expansion

Regional Trends

In 2024, the North America captured 39.4% of the revenue share in Angina Pectoris Drugs market.

North America Angina Pectoris Drugs Market Trends

North America Angina Pectoris Drugs market is driven by the rising preference for minimally invasive procedures, along with factors such as unhealthy lifestyle habits, favorable regulatory policies, and a growing prevalence of cardiac diseases. The demand for minimally invasive treatments and innovative drug formulations is driving market expansion across the region. Favorable regulatory policies, ongoing clinical research, and the availability of comprehensive healthcare coverage further support market growth. Additionally, lifestyle-related risk factors such as obesity, smoking, and high-stress levels contribute to the increasing incidence of angina, fueling the need for effective treatment options. With continuous advancements in cardiovascular care and a growing focus on personalized medicine, the market in North America is expected to expand steadily in the coming years.

U.S. Angina Pectoris Drugs Market Trends

The U.S. Angina Pectoris Drugs market is set for strong growth during the forecast period, driven by increased awareness, greater accessibility to treatments, and supportive insurance policies. With more patients opting for prescribed therapies, the market is expected to expand significantly.

Asia Pacific Angina Pectoris Drugs Market Trends

Asia Pacific region is experiencing the fastest growth in Angina Pectoris Drugs market. The market expansion is primarily fueled by rapid urbanization, shifting lifestyle patterns, and an increasing prevalence of cardiovascular diseases are driving demand in key markets like China, India, and Japan. Rising healthcare expenditures and a stronger focus on preventive care are also contributing to Angina Pectoris Drugs market growth.

China Angina Pectoris Drugs Market Trends

China’s Angina Pectoris Drugs market is expected to expand significantly due to its aging population and increasing rates of unhealthy dietary habits. The rising incidence of cardiovascular diseases among the elderly, coupled with limited awareness of preventive healthcare, is pushing demand for effective treatments.

India Angina Pectoris Drugs Market Trends

India’s Angina Pectoris Drugs market is poised for notable growth, supported by increasing awareness of cardiovascular diseases and the importance of early diagnosis and treatment. Government-led health initiatives and awareness programs are also playing a crucial role in driving Angina Pectoris Drugs market expansion.

Europe Angina Pectoris Drugs Market Trends

Europe is forecasted to experience steady growth in Angina Pectoris Drugs market during the forecast period, fueled by rising incidence of cardiovascular diseases, advancements in treatment technologies, increased awareness, and government-backed health initiatives. Additionally, hospital research on angina medications and the expanding elderly population contribute to market expansion.

Germany Angina Pectoris Drugs Market Trends

Germany is anticipated to witness rapid growth due to the rising prevalence of cardiovascular diseases among its aging population. A sedentary lifestyle, smoking, and other unhealthy habits are increasing the demand for angina pectoris treatments in the country.

UK Angina Pectoris Drugs Market Trends

The UK market is also on an upward trajectory, driven by heightened awareness of angina pectoris and its associated risk factors. Public health campaigns focused on cardiovascular education are further fueling demand for angina medications.

Angina Pectoris Drugs Market Trends

• Shift Toward Novel Therapies: Increasing focus on targeted biologics and gene therapy to improve outcomes and reduce side effects
• Growth of Extended-Release and Combination Therapies: Enhancing patient adherence and treatment efficacy through advanced drug formulations
• Increased R&D Investments: Pharmaceutical companies are prioritizing innovative drug delivery systems, such as transdermal patches and sustained-release oral medications
• Rising Demand for Cost-Effective Generics and Biosimilars: Driving market expansion, especially in emerging economies
• Regulatory Approvals and Fast-Track Designations: Accelerating drug development pipelines for promising angina treatments
• Advancements in Personalized Medicine: AI-driven drug discovery and precision treatment approaches are shaping future therapies
• Integration of Telemedicine and Digital Health Solutions: Improving patient monitoring, medication adherence, and early intervention strategies

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Real-Time Data Updates:
• Competitor Benchmarking
• Market Trends Heatmap
• Custom Research Queries
• Market Sentiment Analysis
• Demographic and Geographic Insights

Book Demo

Get Access Now

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Competitive Landscape

The competitive landscape of the Angina Pectoris Drugs market is characterized by the presence of several global and regional pharmaceutical companies focusing on the development and commercialization of effective treatments. Key players include AstraZeneca, Pfizer, Novartis, Merck & Co., Bayer AG, Sanofi, Amgen, and GlaxoSmithKline, among others. These companies are actively engaged in new drug development, strategic collaborations, and mergers & acquisitions to strengthen their market position. The market is driven by increasing R&D investments, the launch of novel drug formulations, and advancements in drug delivery systems. Additionally, the rising prevalence of angina pectoris and cardiovascular diseases is fueling competition, with a growing focus on cost-effective generics and patient-centric therapies. Regulatory approvals and market access strategies play a crucial role in determining the competitive edge, while biosimilars and alternative treatment approaches, such as gene therapy and regenerative medicine, are emerging as potential disruptors in the market.

The key players in the global Angina Pectoris Drugs market include - Pfizer Inc., Bayer AG, AstraZeneca, Gilead Sciences, Novartis AG, GlaxoSmithKline Plc., Merck & Co., Inc., Amgen Inc., Eli Lilly and Company, Otsuka Pharmaceutical Co., Ltd., Sanofi S.A., Boehringer Ingelheim International GmbH. among others.

Recent Market Developments

• In May 2024, Novartis and AC Health formed a partnership aimed at enhancing access to innovative treatments for cancer, cholesterol management, and heart failure, while also focusing on patient empowerment through integrated cardiovascular and cancer care
• In August 2024, AstraZeneca announced encouraging outcomes from a Phase II trial of its latest angina treatment, highlighting strong efficacy and a favorable safety profile
• In July 2024, Pfizer launched a Phase III clinical trial for a new extended-release version of one of its angina drugs, designed to improve patient adherence and enhance treatment effectiveness
• In July 2023, Riparian Pharmaceuticals collaborated with Pfizer to advance cardiovascular drug development, granting Pfizer exclusive rights to a preclinical program designed to support Riparian’s efforts in identifying new vasoprotective drug targets

Angina Pectoris Drugs Market Segments Covered in the report:

Type

• Stable Angina
• Unstable Angina
• Microvascular Angina
• Prinzmetal Angina

Drug Class

• Beta Blockers
  • Metoprolol
  • Atenolol
  • Propranolol
  • Others
• Calcium Antagonists
• Nitrates
  • Nitroglycerin
  • Isosorbide Mononitrate
  • Isosorbide Dinitrate
• Anticoagulants
  • Heparin
  • Warfarin
  • Novel Oral Anticoagulants (NOACs)
• Anti-Platelets
  • Aspirin
  • Clopidogrel
  • Ticagrelor
  • Others
• Other Drug Classes

End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Angina Pectoris Drugs Market Regions and Countries:

North America

• U.S.
• Canada
• Mexico

Europe

• Germany
• France
• U.K.
• Italy
• Spain
• Nordic Countries
• Benelux Union
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• South-East Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Rest of Latin America

The Middle-East and Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of Middle-East Africa